Wells Fargo maintains American Well at Overweight, raises price target to $18 from $16

Wells Fargo raised its price target for American Well to $18 from $16, indicating a 12.5% increase. This target suggests a 41.3% upside from the Nov 3 close of $12.74. The firm maintained its Overweight rating on the stock.

Original reporting
Published Nov 4, 2026, 3:36 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 3:40 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Wells Fargo maintains American Well at Overweight, raises price target to $18 from $16 — source image
Decision brief

The 30-second read

$AMWLBullishMed
01

Why it matters

The analyst upgrade could trigger short-covering and new buying, but execution risk remains.

02

Market read

A fresh price target upgrade provides a short-term catalyst for AMWL.

03

What to watch

Potential regulatory scrutiny of telehealth reimbursement could limit upside.

Relevance 6/10Novelty 7/10Timing: today

Background

American Well (AMWL) is a telehealth platform that has been volatile amid shifting healthcare policies.

Company-level read

Ticker impact

$AMWLBullishHigh confidence
Context

Wells Fargo raised its price target on American Well to $18 from $16, indicating a fresh bullish analyst upgrade.

Expected impact

potential upward pressure as investors price in the higher target

Evidence & confidence

The new target implies a 41% upside from the current price, which may attract buying interest.

Market effects

The upgrade may lift other telehealth peers as the sector gains credibility.

U.S. healthcare investors could see modest inflows.

Limited to U.S. markets; no immediate global ripple.

Counterpoint

The target raise may be premature if upcoming earnings miss expectations.

Key entities

  • Wells Fargo

    Raised AMWL price target to $18.

Related articles

$AMWLMed

American Well Corp (AMWL) Q3 2026 Earnings Call Highlights: Revenue Beat, Raised Guidance

American Well Corp (AMWL) reported Q3 2026 revenue of $49M, down 12.9% YoY. Subscription revenue fell 22.5% due to churn. Platform visits dropped 30.5% YoY. The VA letter of intent is non-binding, and the DHA contract conversion is pending. CEO Dr. Ido Schoenberg expressed optimism about negotiations and potential growth opportunities. The company expects Q4 adjusted EBITDA breakeven and raised guidance.

$AMWLMedAI 8/10

What American Well (AMWL) Said on Its Q3 Earnings Call

Amwell (AMWL) reported Q3 earnings with virtual primary care visits up 41% YoY, but total platform visits down 30.5%. Gross profit was $26M with a 53% margin. Q4 revenue is forecasted at $48M-$50M, with adjusted EBITDA expected to break even or turn positive. The company raised its full-year 2026 outlook, now expecting revenue of $204M-$206M and a reduced adjusted EBITDA loss. Amwell also discussed potential government contracts, including a nonbinding letter of intent from the VA.

$AMWLHigh

American Well Corp (AMWL): AMWELL® ANNOUNCES RESULTS FOR THE third QUARTER 2026

American Well Corp (AMWL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 AMWELL® ANNOUNCES RESULTS FOR THE third QUARTER 2026 BOSTON, November 3 , 2026 –Amwell ® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based technology-enabled healthcare platform, today announced financial results for the third quarter ended September 30,

$AMWLMedAI 8/10

American Well (AMWL) Q2 2026 Earnings Call Transcript

American Well (AMWL) reported Q2 2026 revenue of $52 million, down 26.6% year over year, with subscription revenue of $25.7 million and AMG revenue of $24.4 million. Adjusted EBITDA loss was $1.15 million and net loss was $9.6 million. Full-year guidance was narrowed to $200-$205 million revenue and improved adjusted EBITDA loss to $9-$7 million. The Defense Health Agency issued an intent to award a sole-source contract.